EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida und 9 weitere

Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 981-1002

DOI: 10.3350/cmh.2024.1088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Tomoko Aoki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Signal Transduction. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, SRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells.

Methods

Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications.

Results

Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The “rich metabolism” subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, wellto-moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatorymicroenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32–S37) mutations, and an immune-desert/excluded phenotype. The “glycolysis” subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis.

Conclusions

The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularSignal TransductionHumansMaleFemaleMiddle Agedbeta CateninGlycolysisLiver

Stichwörter der Autor:innen

Carcinoma, hepatocellularCell differentiationGene expression profilingGlycolysisMetabolism

Substanzen

beta Catenin

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Mie University, Tsu, Japan.
  • Department of Radiology, Kansai Medical University Medical Center, Osaka, Japan.
  • Institute of Advanced Clinical Medicine, Kindai University, Osaka, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • SRF

Zitieren

APA

Aoki, T., Nishida, N., Kurebayashi, Y., Sakai, K., Fujiwara, N., Tsurusaki, M., Hanaoka, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Ueshima, K., Minami, Y., Takebe, A., Murase, T., Kamei, K., Nakai, T., Matsumoto, I., …, & Kudo, M. (2025). Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway. Clinical and Molecular Hepatology, 31(3), 981-1002. https://doi.org/10.3350/cmh.2024.1088

Vancouver

Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, et al. Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway. Clinical and Molecular Hepatology. 2025;31(3):981-1002. doi:10.3350/cmh.2024.1088

BibTeX
@article{Aoki2025,
  author = {Aoki, Tomoko and Nishida, Naoshi and Kurebayashi, Yutaka and Sakai, Kazuko and Fujiwara, Naoto and Tsurusaki, Masakatsu and Hanaoka, Kohei and Morita, Masahiro and Chishina, Hirokazu and Takita, Masahiro and Hagiwara, Satoru and Ida, Hiroshi and Ueshima, Kazuomi and Minami, Yasunori and Takebe, Atsushi and Murase, Takaaki and Kamei, Keiko and Nakai, Takuya and Matsumoto, Ippei and Nishio, Kazuto and Kudo, Masatoshi},
  title = {Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {981--1002},
  doi = {10.3350/cmh.2024.1088}
}
Kostenlos starten →